SMCR2: A protein target for cancer, autoimmune disorders, and neurodegenerative diseases

Target Name: SMCR2

NCBI ID: G105371564

SMCR2

Other Name(s): TCONS_00025215 | Smith-Magenis syndrome chromosome region, candidate 2 (non-protein coding) | Smith-Magenis syndrome chromosome region, candidate 2

SMCR2: A protein target for cancer, autoimmune disorders, and neurodegenerative diseases

SMCR2 (SMCR2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and intestines. It is a member of the T-cell receptor (TCR) family, which is a group of proteins that play a critical role in the immune system.

SMCR2 has been identified as a potential drug target for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its unique structure and location in the body make it an attractive target for drug developers because it is difficult to target with small molecules.

SMCR2 is a 21-kDa protein that consists of a 194 amino acid chain. It is expressed in various tissues throughout the body, including the brain, heart, kidneys, and intestines. It is a member of the TCR family, which is a group of proteins that play a critical role in the immune system. SMCR2 is expressed in a variety of tissues and is involved in several different processes in the body, including cell signaling, DNA replication, and immune response.

SMCR2 has been shown to be involved in several different diseases and conditions. For example, it has been shown to be involved in the development and progression of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. In addition, SMCR2 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

SMCR2 is also a potential drug target for several other conditions that are treated with small molecules. Its unique structure and location in the body make it an attractive target for drug developers because it is difficult to target with small molecules. This means that small molecules, which are often used to treat diseases, may not be effective in treating SMCR2-related diseases.

SMCR2 has also been shown to be involved in several different signaling pathways in the body. For example, it has been shown to be involved in the DNA replication pathway, which is critical for the development and progression of cancer. It has also been shown to be involved in the cell signaling pathway, which is responsible for the communication between cells and is involved in many different processes in the body.

SMCR2 is also a potential biomarker for several diseases. Its expression has been shown to be associated with the development of cancer, autoimmune disorders, and neurodegenerative diseases. This makes it an attractive target for researchers to study and to develop biomarkers for these diseases.

In conclusion, SMCR2 is a protein that is expressed in various tissues throughout the body and is involved in several different processes in the body. Its unique structure and location in the body make it an attractive target for drug developers because it is difficult to target with small molecules. Its involvement in several different diseases and conditions makes it an attractive target for researchers to study and to develop biomarkers for these diseases. Further research is needed to fully understand the role of SMCR2 in the immune system and to develop effective treatments for SMCR2-related diseases.

Protein Name: Smith-Magenis Syndrome Chromosome Region, Candidate 2

The "SMCR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMCR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets